Serum level of MMP-3 in patients with oral squamous cell carcinoma - lack of association with clinico-pathological features

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue 9, 2012, Pages 4545-4548

  Tadbir, Azadeh Andisheh ^a   Purshahidi, Sara ^b   Ebrahimi, Hooman ^b   Khademi, Bijan ^c,d   Malekzadeh, Mahzad ^d   Mardani, Maryam ^b   Taghva, Masumeh ^a   Sardari, Yasaman ^b  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Diagnosis; MMP 3; Oral squamous cell carcinoma; Prognosis; Serum

Indexed keywords

EID: 84874003740     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.9.4545     Document Type: Article

References (27)

1. Agnihotri R, Crawford HC, Haro H, et al (2001). Osteopontin, a novel substrate for matrix metalloproteinase-3 (stromelysin-1) and matrix metalloproteinase-7 (matrilysin). J Biol Chem, 276, 28261-7.
2. Amǎlinei C, Cǎruntu ID, Bǎlan RA (2007). Biology of metalloproteinases. Rom J Morphol Embryol, 48, 323-34.
3. Baker EA, Leaper DJ, Hayter JP, Dickenson AJ (2006). The matrix metalloproteinase system in oral squamous cell carcinoma. J Oral Maxillofac Surg, 44, 482-6.
4. Bar-Or A, Nuttall RK, Duddy M, et al (2003). Analyses of all matrix metalloproteinase members in leukocytes emphasize monocytes as major inflammatory mediators in multiple sclerosis. Brain, 126, 2738-49.
5. Choi P, Jordan CD, Mendez E, et al (2008). Examination of Oral Cancer Biomarkers by Tissue Microarray Analysis. Arch Otolaryngol Head Neck Surg, 134, 539-46.
6. Constantin A, Lauwers-Cancès V, Navaux F, et al (2002). Stromelysin 1 (matrix metalloproteinase 3) and HLA-DRB1 gene polymorphisms- association with severity and progression of rheumatoid arthritis in a prospective study. Arthritis Rheum, 46, 1754-62.
7. Egeblad M, Werb Z (2002). New functions for the matrix metalloproteinases in cancer progression. Nature, 2, 161-74.
8. Erdem NF, Carlson ER, Gerard DA, Ichiki AT (2007). Characterization of 3 oral squamous cell carcinoma cell lines with different invasion and/or metastatic potentials. J Oral Maxillofac Surg, 65, 1725-33.
9. Fang SM, Jin X, Li Y, et al (2005). Correlation of matrix metalloproteinase-3 polymorphism to genetic susceptibility and lymph node metastasis of non-small cell lung cancer. Ai Zheng, 24, 305-10.
10. Gershtein ES, Korotkova EA, Prorokov VV, Kushlinsky NE (2008). Matrix metalloproteinases 2, 3, 13 and their type 2 tissue inhibitor in tumors and plasma of patients with colorectal cancer. Bull Exp Biol Med, 145, 362-6.
11. Jeffery N, McLean MH, Ei-Omar EM, Murray GI (2009). The matrix metalloproteinase/tissue inhibitor of matrix metalloproteinase profile in colorectal polyp cancers. Histopathology, 54, 820-8.
12. Komosinska-Vassev K, Olczyk P, Winsz-Szczotka K, et al (2011). Age- and gender-dependent changes in connective tissue remodeling: physiological differences in circulating MMP-3, MMP-10, TIMP-1 and TIMP-2 level. Gerontology, 57, 44-52.
13. Kurahara SI, Shinohara M, Ikebe T, et al (1999). Expression of MMPs, MT-MMP, and TIMPs in squamous cell carcinoma of the oral cavity: correlations with tumor invasion and metastasis. Head Neck, 21, 627-38.
14. Kusukawa J, Sasaguri Y, Morimatsu M, Kameyama T (1995). Expression of matrix metalloproteinase-3 in stage I and II squamous, cell carcinoma of the oral cavity. J Oral Maxillofac Surg, 3, 530-4.
15. Linkow F, Lisovich A, Yurkovetsky Z, et al (2007). Early detection of head and neck cancer: development of a novelscreening tool using multiplexed immunobead-based biomarker profiling. Cancer Epidemiol Biomarkers Prev, 16, 102-7.
16. Liu HQ, Song S, Wang JH, Zhang SL (2011). Expression of MMP-3 and TIMP-3 in gastric cancer tissue and its clinical significance. Oncol Lett, 2, 1319-22.
17. Liu SY, Liu YC, Huang WT, et al (2007). Requirement of MMP-3 in anchorage-independent growth of oral squamous cell carcinomas. J Oral Pathol Med, 36, 430-5.
18. Moilanen M (2003). Tumor-associated trypsinogen-2 (trypsinogen-2) activates procollagenases (MMP-1, -8, -13) and stromelysin-1 (MMP-3) and degrades type I collagen. Biochemistry, 242, 5414-20.
19. Sternlicht MD, Werb Z (2001). How matrix metalloproteinases regulate cell behavior. Annu. Rev Cell Biol, 17, 463-516.
20. Tas F, Duranyildiz D, Oguz H, et al (2008). Circulating levels of vascular endothelial growth factor (VEGF), matrix metalloproteinase-3 (MMP-3), and BCL-2 in malignant melanoma. Med Oncol, 25, 431-6.
21. Thrailkill KM, Moreau CS, Cockrell G, et al (2005). Physiological matrix metalloproteinase concentrations in serum during childhood and adolescence, using Luminex Multiplex technology. Clin Chem Lab Med, 43, 1392-9.
22. Tolboom TC, Pieterman E, van der Laan WH, et al (2002). Invasive properties of fibroblast-like synoviocytes: correlation with growth characteristics and expression of MMP-1, MMP-3, and MMP-10. Ann Rheum Dis, 61, 975-80.
23. Tsukifuji R, Tagawa K, Hatamochi A, Shinkai H (1999). Expression of matrix metalloproteinase-1, -2 and -3 in SCC and actinic keratosis. Br J Cancer, 80, 1087-91
24. Vairaktaris E, Yapijakis C, Vasiliou S, et al (2007). Association of -1171 promoter polymorphism of matrix metalloproteinase-3 with increased risk for oral cancer. Anticancer Res, 27, 4095-100.
25. Wiegand S, Dünne AA, Müller HH, et al (2005). Metaanalysis of the significance of matrix metalloproteinases for lymph node disease in patients with head and neck squamous cell carcinoma. Cancer, 104, 94-100.
26. Yeh YC, Sheu BS, Cheng HC, et al (2010). Elevated serum matrix metalloproteinase-3 and -7 in H.pylori-related gastric cancer can be biomarkers correlating with a poor survival. Dig Dis Sci, 55, 1649-57.
27. Yin L, Morita A, Tsuji T (2000). Alterations of extracellular matrix induced by tobacco smoke extract. Arch Dermatol Res, 292, 188-94